Home / Health / Absci Stock Surges on Promising Drug Trial Results
Absci Stock Surges on Promising Drug Trial Results
27 Jun
Summary
- Absci's investigational antibody ABS-201 shows favorable safety profile.
- Early trial data support further evaluation in hair loss and endometriosis.
- Company successfully raised $100 million to fund ABS-201 development.
Absci Corporation announced positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201. The clinical-stage biopharmaceutical company reported that the early-stage trial data demonstrate a favorable safety, pharmacokinetic, and immunogenicity profile for ABS-201. These findings support its continued evaluation for applications in androgenetic alopecia (AGA) and endometriosis.
The ongoing Phase 1 study, a randomized, double-blind, placebo-controlled trial, has advanced into its multiple ascending dose portion. Interim data from 32 healthy adults in single ascending dose cohorts indicate ABS-201 was generally well-tolerated with no serious adverse events reported. Pharmacokinetic findings suggest a potential half-life of at least 65 days, which could support infrequent dosing.
In parallel, Absci priced an underwritten offering of 13.5 million shares at $7.41 per share, expecting gross proceeds of approximately $100 million. The company plans to utilize these net proceeds to advance ABS-201 for both AGA and endometriosis indications, alongside general corporate purposes and working capital.
